0001104659-13-034759.txt : 20130430 0001104659-13-034759.hdr.sgml : 20130430 20130430081640 ACCESSION NUMBER: 0001104659-13-034759 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130430 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130430 DATE AS OF CHANGE: 20130430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MAGELLAN HEALTH SERVICES INC CENTRAL INDEX KEY: 0000019411 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 581076937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06639 FILM NUMBER: 13794463 BUSINESS ADDRESS: STREET 1: 6950 COLUMBIA GATEWAY STREET 2: STE 400 CITY: COLUMBIA STATE: MD ZIP: 21046 BUSINESS PHONE: 4109531000 FORMER COMPANY: FORMER CONFORMED NAME: CHARTER MEDICAL CORP DATE OF NAME CHANGE: 19920703 8-K 1 a13-10324_28k.htm 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):

April 30, 2013

 

MAGELLAN HEALTH SERVICES, INC.

(Exact Name of Registrant as Specified in Charter)

 

DELAWARE

 

1-6639

 

58-1076937

(State or Other Jurisdiction

 

(Commission File

 

(IRS Employer

of Incorporation)

 

Number)

 

Identification No.)

 

55 NOD ROAD

 

 

AVON, CONNECTICUT

 

06001

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (860) 507-1900

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02. Results of Operations and Financial Condition

 

On April 30, 2013, Magellan Health Services, Inc. (the “Company”) reported operating results for the quarter ended March 31, 2013 and updated its guidance for the full year.

 

Attached and incorporated herein by reference as Exhibit 99.1 is a copy of the press release dated April 30, 2013.

 

Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibits

 

(a)  Financial Statements of business acquired:  Not applicable.

 

(b)  Pro forma financial information:  Not applicable.

 

(d)  Exhibits:

 

Exhibit Number

 

Description

99.1

 

Registrant’s press release dated April 30, 2013.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

MAGELLAN HEALTH SERVICES, INC.

 

 

 

 

Date: April 30, 2013

By:

/s/ Jonathan N. Rubin

 

 

Name:

Jonathan N. Rubin

 

 

Title:

Executive Vice President and Chief Financial Officer

 

3


EX-99.1 2 a13-10324_2ex99d1.htm EX-99.1

Exhibit 99.1

 

NEWS RELEASE

 

GRAPHIC

 

Media Contact: David Carter, dwcarter@magellanhealth.com, (860) 507-1909

Investor Contact: Renie Shapiro, rshapiro@magellanhealth.com, (877) 645-6464

 

MAGELLAN HEALTH SERVICES REPORTS

FIRST QUARTER 2013 FINANCIAL RESULTS

 

- Lowers guidance for the year -

 

AVON, Conn. — April 30, 2013 — Magellan Health Services Inc. (NASDAQ: MGLN) today reported financial results for the first quarter 2013, as summarized below. For the quarter ended March 31, 2013, the company reported net revenue of $821.8 million, segment profit of $69.2 million, and net income of $28.1 million or $1.01 per diluted common share.  Segment profit represents income from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes.

 

Financial Results

 

 

 

Three Months Ended March 31

 

(Millions, except per share results)

 

2013

 

2012

 

Increase/
(Decrease)

 

Revenue

 

$

821.8

 

$

773.2

 

6.3

%

Segment Profit

 

69.2

 

55.4

 

24.9

%

Net Income

 

28.1

 

20.8

 

35.1

%

Earnings per Share

 

1.01

 

0.75

 

34.7

%

 

As of March 31, 2013, the company had unrestricted cash and investments of $312.5 million.

 

“Magellan had a strong first quarter, with good performance across our businesses,” said Barry M. Smith, chief executive officer.  “This is an important year as we continue to execute on our Magellan Complete Care and Magellan Pharmacy Solutions initiatives.  In each of those areas, we continue to build out our capabilities in order to fuel aggressive growth, and we are seeing traction in the market.  Magellan Complete Care, for example, is well positioned for market entry in Florida, having just completed its review as part of the final regulatory approval process.  We expect to begin enrolling members by the third quarter with the ultimate objective of becoming a specialty plan serving Medicaid recipients with Serious Mental Illness.

 

“During the quarter, we were disappointed about the award of the Maricopa County, Arizona contract to another vendor for the period beginning October 1, 2013.  In response, we filed a formal protest regarding the State’s decision as well as a lawsuit against one of the sponsors of the winning vendor.  Our initial protest was denied, and we intend to file an appeal.  As we pursue those avenues, we continue to serve the people of Arizona with the highest standards of service.  It’s important to put this one contract in perspective and assess it in light of our future growth opportunities.”

 

Magellan Health Services—55 Nod Road, Avon CT 06001—www.MagellanHealth.com

 



 

Outlook

 

“Our strong results and financial position allow us to continue to invest in our Magellan Complete Care and Magellan Pharmacy Solutions strategies, which provides meaningful opportunities for future growth,” said Jonathan N. Rubin, chief financial officer.

 

“With regard to the full year 2013, we are revising our guidance and now expect net revenue in the range of $3.3 billion to $3.5 billion, net income of $90 million to $108 million, and segment profit of $245 million to $265 million. We are adjusting our diluted EPS guidance to be in the range of $3.27 to $3.93, which reflects the lower net income as well as the impact of share repurchase activity through April 25, 2013, but does not consider any potential future share repurchases.  The decrease in our guidance is driven primarily by the assumption that our contract in Maricopa County does not extend beyond September 30, 2013, partially offset by the impact of favorable prior year care development and cost trends.”

 

Earnings Results Conference Call

 

Management will host a conference call at 11:00 a.m. Eastern Time on Tuesday, April 30, 2013.  To participate in the conference call, interested parties should call 1-800-857-1812 and reference the pass code First Quarter Earnings Call 2013 approximately 15 minutes before the start of the call.  The conference call will also be available via a live Webcast at Magellan’s investor relations page at www.MagellanHealth.com.

 

About Magellan Health Services:  Headquartered in Avon, Conn., Magellan Health Services Inc. is a leading specialty health care management organization with expertise in managing behavioral health, radiology and specialty pharmaceuticals, as well as pharmacy benefits programs.  Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve.  As of March 31, 2013, Magellan’s customers include health plans, employers and government agencies, serving approximately 33.9 million members in our behavioral health business, 17.1 million members in our radiology benefits management segment, and 7.4 million members in our medical pharmacy management product.  In addition, the pharmacy solutions segment served 41 health plans and employers, 24 states and the District of Columbia, and several pharmaceutical manufacturers.  For more information, visit www.MagellanHealth.com.

 

Cautionary Statement

 

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties.  All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2013 revenue, net income, segment profit, earnings per share, strategy and growth. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company’s customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company’s

 

2



 

risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the company’s Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission on February 28, 2013, and the company’s subsequent Quarterly Reports on Form 10-Q filed during 2013.  Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure.  Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.

 

Media Contact

David W. Carter

860-507-1909

DWCarter@MagellanHealth.com

 

Investor Contact

Renie Shapiro

877-645-6464

RShapiro@MagellanHealth.com

 

# # #

 

3



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

FOR THE THREE MONTHS ENDED MARCH 31,

(Unaudited)

(In thousands, except per share amounts)

 

 

 

 

2012

 

2013 (1)

 

Net revenue:

 

 

 

 

 

Managed care and other

 

$

686,059

 

$

727,640

 

Dispensing

 

87,154

 

94,121

 

Total net revenue

 

773,213

 

821,761

 

 

 

 

 

 

 

Cost and expenses:

 

 

 

 

 

Cost of care

 

505,293

 

529,931

 

Cost of goods sold

 

81,038

 

88,608

 

Direct service costs and other operating expenses (2)

 

136,589

 

139,627

 

Depreciation and amortization

 

14,781

 

16,170

 

Interest expense

 

600

 

610

 

Interest income

 

(412

)

(353

)

 

 

737,889

 

774,593

 

Income before income taxes

 

35,324

 

47,168

 

Provision for income taxes

 

14,534

 

19,110

 

Net income

 

20,790

 

28,058

 

Other comprehensive income (loss) (3) 

 

173

 

(77

)

Comprehensive income

 

$

20,963

 

$

27,981

 

 

 

 

 

 

 

Weighted average number of common shares outstanding — basic

 

27,199

 

27,110

 

Weighted average number of common shares outstanding — diluted

 

27,747

 

27,648

 

 

 

 

 

 

 

Net income per common share — basic

 

$

0.76

 

$

1.03

 

Net income per common share — diluted

 

$

0.75

 

$

1.01

 

 


(1) For a more detailed discussion of Magellan’s results for the quarterly period ended March 31, 2013, refer to the Company’s Quarterly Report on Form 10-Q, which will be filed with the SEC on April 30, 2013, and the live broadcast or taped replay of the Company’s earnings conference call on April 30, 2013, which will be available at www.MagellanHealth.com.

 

(2) Includes stock compensation expense of $5,102 and $5,638 for the three months ended March 31, 2012 and 2013, respectively.

 

(3) Net of income tax provision (benefit) of $111 and $(52) for the three months ended March 31, 2012 and 2013, respectively.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31,

(Unaudited)

(In thousands)

 

 

 

2012

 

2013 (1)

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

20,790

 

$

28,058

 

 

 

 

 

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

14,781

 

16,170

 

Non-cash interest expense

 

177

 

184

 

Non-cash stock compensation expense

 

5,102

 

5,638

 

Non-cash income tax expense (benefit)

 

2,696

 

(630

)

Non-cash amortization on investments

 

1,760

 

2,508

 

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

 

 

 

 

 

Restricted cash (2) 

 

852

 

4,764

 

Accounts receivable, net

 

(12,106

)

(8,359

)

Pharmaceutical inventory

 

(3,502

)

(2,004

)

Other assets

 

6,068

 

(2,039

)

Accounts payable and accrued liabilities

 

(26,724

)

(15,285

)

Medical claims payable and other medical liabilities

 

19,201

 

15,752

 

Tax contingencies

 

690

 

601

 

Other

 

(216

)

521

 

Net cash provided by operating activities

 

29,569

 

45,879

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Capital expenditures

 

(14,505

)

(11,382

)

Purchase of investments

 

(61,977

)

(66,596

)

Maturity of investments

 

97,168

 

47,647

 

Net cash provided by (used in) investing activities

 

20,686

 

(30,331

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payments to acquire treasury stock

 

 

(24,830

)

Proceeds from exercise of stock options and warrants

 

2,197

 

9,675

 

Payments on capital lease obligations

 

 

(414

)

Other

 

(743

)

(1,022

)

Net cash provided by (used in) financing activities

 

1,454

 

(16,591

)

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

51,709

 

(1,043

)

Cash and cash equivalents at beginning of period

 

119,862

 

189,464

 

Cash and cash equivalents at end of period

 

$

171,571

 

$

188,421

 

 


(1) The Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013 will be filed with the SEC on April 30, 2013.

 

(2)  Includes the impact of the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change.  During the three months ended March 31, 2012 restricted investments of $4,419 were shifted to restricted cash that resulted in an operating cash flow (use), with restricted cash of $5,016 shifted to restricted investments during the three months ended March 31, 2013 that resulted in an operating cash flow source.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT

FOR THE THREE MONTHS ENDED MARCH 31,

(Unaudited)

(In thousands)

 

 

 

2012

 

2013 (1)

 

Managed care and other revenue

 

 

 

 

 

- Commercial

 

$

180,524

 

$

187,837

 

- Public Sector

 

388,888

 

406,620

 

- Radiology Benefits Management

 

76,857

 

90,278

 

- Pharmacy Solutions (2)

 

60,898

 

58,150

 

- Elimination (2) 

 

(21,108

)

(15,245

)

Total net revenue

 

686,059

 

727,640

 

 

 

 

 

 

 

Dispensing revenue - Pharmacy Solutions

 

87,154

 

94,121

 

 

 

 

 

 

 

Cost of care

 

 

 

 

 

- Commercial

 

112,172

 

113,271

 

- Public Sector (2) 

 

344,312

 

355,379

 

- Radiology Benefits Management

 

50,410

 

58,067

 

- Pharmacy Solutions

 

19,507

 

18,459

 

- Elimination (2) 

 

(21,108

)

(15,245

)

Total cost of care

 

505,293

 

529,931

 

 

 

 

 

 

 

Cost of goods sold - Pharmacy Solutions

 

81,038

 

88,608

 

 

 

 

 

 

 

Direct service costs and other operating expenses

 

 

 

 

 

- Commercial

 

42,362

 

41,392

 

- Public Sector

 

20,597

 

25,643

 

- Radiology Benefits Management

 

13,486

 

13,371

 

- Pharmacy Solutions

 

29,019

 

29,561

 

- Corporate

 

31,125

 

29,660

 

Total direct service costs and other operating expenses

 

136,589

 

139,627

 

 

 

 

 

 

 

Stock compensation expense (3)

 

 

 

 

 

- Commercial

 

(267

)

(133

)

- Public Sector

 

(287

)

(307

)

- Radiology Benefits Management

 

(400

)

(434

)

- Pharmacy Solutions

 

(230

)

(320

)

- Corporate

 

(3,918

)

(4,444

)

Total stock compensation expense

 

(5,102

)

(5,638

)

 

 

 

 

 

 

Segment profit (loss)

 

 

 

 

 

- Commercial

 

26,257

 

33,307

 

- Public Sector

 

24,266

 

25,905

 

- Radiology Benefits Management

 

13,361

 

19,274

 

- Pharmacy Solutions

 

18,718

 

15,963

 

- Corporate and Elimination

 

(27,207

)

(25,216

)

Total segment profit

 

$

55,395

 

$

69,233

 

 

 

 

 

 

 

Reconciliation of segment profit to income before income taxes:

 

 

 

 

 

Segment profit

 

$

55,395

 

$

69,233

 

Stock compensation expense

 

(5,102

)

(5,638

)

Depreciation and amortization

 

(14,781

)

(16,170

)

Interest expense

 

(600

)

(610

)

Interest income

 

412

 

353

 

Income before income taxes

 

$

35,324

 

$

47,168

 

 


(1) The Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2013 will be filed with the SEC on April 30, 2013.

 

(2) Public Sector has subcontracted with Pharmacy Solutions to provide pharmacy benefits management services on a limited risk basis for one of Public Sector’s customers.  As such, revenue and cost of care related to this intersegment arrangement are eliminated.

 

(3) Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis.

 


GRAPHIC 3 g103242mm01i001.jpg GRAPHIC begin 644 g103242mm01i001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#;BB>:5(HQ MEW8*H]S6E_PC.J_\\%_[^"JFF?\`(4M?^NR_SKT2O0K590:2."C2C-.YPW_" M,ZK_`,\%_P"_@JO>Z1>Z?$LMS&%5CM!#`\UZ#6!XO_Y!L/\`UU'\C6=.O*4D MF:5*$8Q;0SP?_P`>EQ_UT'\JZ*N=\'_\>EQ_UT'\JZ*L*W\1FU'^&@HHHK(U M"BBB@`HHHH`****`"BBB@`HHHH`****`/.],_P"0I:_]=E_G7H4CK%&TCL%1 M`2Q/0`5Y[IG_`"%+7_KLO\Z[G5/^03>?]<'_`/0377BOB1RX;9E>Q\1Z-J=E M/>V.I6]Q;6V3-*CY6/`RKZ?K6AQ76F7D5W`+C9YD39&0#D?K7E/ MA:X;2O`_B&R0X.HZ?;R1#U,CM"?U-=-X/MQ:>!+FV7I#K4Z#\`!6-'^(C6K\ M#.Y\'_\`'I#^1_*L/P[=I8:) MJ-Y)]RW!D;Z*N?Z5QGPKCDTKQ(J3D[M>TE=0)/=_-;^C45OXC"C_``T>N5D: MEXKT#1[Q;/4=7M+6X8`B.20`X/0GT_&M>O)$M]`O?$OCT>([B&VAEF@MUN9< M;H\JV-I(.#\H_*LC4]95E=`Z,&5AD$'((JCJVO:3H21OJNH06:RDB,S-MW$= M<4:#!:VV@:?!8W!N;6*VC2&8G/F(%`!R/45Q/Q3NK*RUGPGTBO9&E4Q M^9E=J_P]Z`.[TW5+#6+,7FG745U;L2HDB;()'6B_U.QTM(GOKJ.W6>40QF1L M;W/11[G%5O#M_I6IZ/'=Z+$L5F[-M40>5R#@_+@=ZYCXK?\`(/T#_L.6W_LU M`'=U5U'4K+2;1KO4+J.VMU(!DD;"@DX%6JX;XP_\D\NO^N\/_H8H`[@$$`@Y M!I:9#_J4_P!T?RI)YDM[>2>0X2-"['T`&30!6L]8TW4+NYM+.]AGN+1ML\:- MEHSSP?3H:NUX_P##3S;+Q?;WDQ(/B2PFNCGNXF8C_P`=->P4`9XU_23J<^F# M4(/MMNADE@W_`#HN`F"/SJU:7=O?VD5W:3+-!,H:.1#D,#W%>/:D3:?&# M5=0SA&=;-_\`MI:L5_\`'D%>B_#[_D0-#_Z\T_E0!SFG,%U*V9B`!*I)/;FN MTU.\M6TJ[5;F(DP.``XR?E-<[_PB>H_WX/\`OH_X5"_AN]CNG\/93PO?H_RN MVN7#A6X)4]#CT]ZVO[`O>?FBYZ_,?\*/^$?O?[T7_?7_`-:IA3A&2?,5*I.4 M;X*P(D2%B=^`>![$U73PG=^#_`!?X4O(K_4M2B;?: M3"<[UMU*``+@?*N3W]*[?PY:OI\4L4[+N=P5VGVKDK02"O&?$JM MI.J>-K&_TN[F.M)')I\L=L949@I'4#@@G]*]FJM]NC^U_9MK;]VW/;[NZLTF MS1NQG>#HI(/!FC131M'(EC$K(XP5(0<$=JYOXDS/9:WX5U'[)O)*+> M$R,%P.PKMX+G[1)*JQLJQ,4W'&"1Z4V&^BF@FF0-MA9E.>^/2BS"Z(-$UB#7 M=-6^MX+F"-F*[+F(QOQ[&N4^+"R_V/H\T5M/<"WU>&:18(R[!5#$G`KLIKQ8 M;'[7Y;NFT,5&,@&DN+Y+6-&EC<%E9MHQD8&2*.5AS(JZ!K]MXBLGNK:VN[=$ MD,96Z@,3$X!R`>W/6N>^+=O/<^`+J.W@DGD\Z$A(D+,0'&>!7:`Y`/K5:WOE MN/-*QNJQDC<1PV"0U\#:LUK%)+/);F)$B0LQ+_+P!]:U_MX^P"[,$@#;=J9&3D@#OCO2B_B-O M!/M8),<#/\)P>OY4^5BYD>7#PC=^$M5\':E'?:G?A)EMYHI?G2V5TP=H`^5< MY_(5ZW5=+Q'%N=K#[0,KGMQGFB&[$UQ)$L3@1DC>1\I(ZBE9CNCRGQ3I=]/> M^.+FWM)FEAFL+BV(C)\PHN#M]>">E=]X#BD@\"Z+%-&T$Y4\=Q5^*=)AP<'N#6=G'8O26Y6M;22WFNI,19F>'S=_FQ@9/9L8/X=*T:*7.Q\J*36DTNDFTHVXIEM;SP7$Q9T,+L74`?-D^M6Z*GF8^5&?;6,MOIKVP$ M(BB@"Y!=;R$?[W8^M6J**QDK,TB[H****DH****`"BB ,B@`HHHH`****`/_9 ` end